DOUGLAS DOLNAK: Open Payments
NPI 1316147085 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 69 payments from 12 companies in 2025. Trend: 2023 $1,684 · 2024 $1,333 · 2025 $2,181
Food & beverage: $2,173Education: $8
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $408 |
| Alkermes, Inc. | 7 | $341 |
| Teva Pharmaceuticals USA, Inc. | 8 | $332 |
| Otsuka America Pharmaceutical, Inc. | 9 | $281 |
| E.R. Squibb & Sons, L.L.C. | 8 | $268 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $175 |
| ABBVIE INC. | 7 | $141 |
| Lundbeck LLC | 3 | $74 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $52 |
Products named: INGREZZA, REXULTI, COBENFY, UZEDY, ARISTADA, CAPLYTA, VRAYLAR, LYBALVI.
Industry payments across CA — which companies pay providers there.
